ClinicalTrials.gg
CompletedNCT05992220ALERT-HCCUpdated Nov 9, 2026

Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion

A Phase 2 interventional study of Atezolizumab plus bevacizumab, combined EBRT to vascular invasion and Atezolizumab plus bevacizumab in Hepatocellular Carcinoma, Hepatocellular Cancer and Hepatocellular Carcinoma Non-resectable, sponsored by Asan Medical Center. Completed at 1 site in South Korea. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Asan Medical Center · Phase 2, Interventional, and Treatment

How we know · 8 judgments · one reading being read again

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2022, registered Jul 2023).
Updated Nov 9, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Enrollment
13th of 41
138 · median 40
Started
2022
with 4 others
Phase 2
19 of 41
8 open now
Registered
29th of 41
by date

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 13th largest by enrollment, is one of 5 that started in 2022, is one of 19 in phase 2, and was the 29th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC). The median overall survival (OS) was notably better in the atezolizumab/bevacizumab group. However, for HCC patients with intrahepatic macrovascular invasion (MVI), the prognosis remains poor, indicating a significant unmet need in this group.

External Beam Radiotherapy (EBRT) has shown promising results in treating HCC with MVI, especially when used in combination with trans-arterial chemoembolization (TACE). It has been reported that radiotherapy may make tumor cells more susceptible to immune-mediated therapy, potentially enhancing the effects of atezolizumab and bevacizumab.

Thus, this study aims to investigate the efficacy and safety of atezolizumab/bevacizumab alone versus atezolizumab/bevacizumab in combination with EBRT in HCC patients with macrovascular invasion.

Read the detailed description

A total of 138 subjects are randomly assigned to one of two treatment groups (69 patients in the atezolizumab+bevacizumab group and 69 patients in the Atezolizumab plus Bevacizumab combined EBRT group).

  • Radiotherapy combination:

    • Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.
    • Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle.
    • The external beam radiotherapy will commence after day 2 of the first cycle of Atezolizumab+Bevacizumab, and will be delivered in accordance with institutional protocol.
  • Atezolizumab+Bevacizumab:

    • Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle.
    • Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle.

Additional study identifiers: This study was also registered on the WHO's International Clinical Trials Registry Platform, CRIS, before the first participant was enrolled (ID: KCT0007365, Date of registration: 2022-06-08).

03

Conditions studied

  • Hepatocellular Carcinoma
  • Hepatocellular Cancer
  • Hepatocellular Carcinoma Non-resectable
  • Hepatocellular Carcinoma Stage IV
  • Liver Cancer

Keywords

  • HCC; vascular invasion; portal vein tumor thrombosis; BCLC stage C
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older than 19 years of age, lower than 80 years of age
  • class A hepatic function
  • (ECOG) performance status (PS) of 0-1
  • Patients with HCC [diagnosed according to AASLD guidelines] invading the intrahepatic vascular system
  • No prior systemic therapy for HCC
  • At least one measurable HCC lesion with ≥ 1cm diameter
  • Adequate hematologic and organ function

    • ≥ 9.0 g/dL
    • ≥ 1,000 /mm3
    • ≥ 50,000/ mm3 without transfusion
  • Total ≤ 2.5 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Treatment history of prior systemic treatment of HCC
  • Liver transplant recipients
  • Patients with peptic ulcer, untreated or incompletely treated varices with bleeding or high-risk for bleeding
  • Any serious illness (e.g., active infection or inflammatory condition) or uncontrolled severe medical comorbidity
  • A history of treated (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years
  • Abdominal/pelvic radiotherapy within 28 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Radiotherapy combination

    Atezolizumab+Bevacizumab, combined EBRT to vascular invasion * Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle. * Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle. * The external beam radiotherapy will commence after day 2 of the first cycle of A+B, and will be delivered in accordance with institutional protocol.

    Radiation: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion

  • Active comparator
    Atezolizumab+Bevacizumab

    * Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21day cycle. * Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21day cycle.

    Drug: Atezolizumab plus bevacizumab

Interventions

  • RadiationAtezolizumab plus bevacizumab, combined EBRT to vascular invasion

    The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol. 3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system. The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator. The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites.

  • DrugAtezolizumab plus bevacizumab

    Drug pages: AtezolizumabBeing read again: the record changed after it was read.Studies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabBeing read again: the record changed after it was read.Studies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atezolizumab plus bevacizumab q3w

06

What researchers measure

Primary outcomes

  1. progression-free survival rate

    Randomization to the first occurrence of disease progression or death from any cause, whichever occurs first

    Time frame: up to approximately 3 years

Secondary outcomes

  1. Overall survival rate

    Randomization to death from any cause, through the end of study

    Time frame: up to approximately 3 years

  2. Objective response

    complete response or partial response as determined by the Investigator according to RECIST V1.1

    Time frame: up to approximately 3 years

  3. Adverse reaction rate

    Adverse reaction rate assessed by CTCAE version 5

    Time frame: through study completion, up to approximately 3 years

  4. Time to deterioration

    The time from randomization to first deterioration (decrease from baseline of ≥10 points) in the patient-reported global health status (GHS) / Quality of life (QoL), physical function, or role function scales of the EORTC QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks

    Time frame: through study completion, up to approximately 3 years

  5. Duration of response

    the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression or death is documented, whichever occurs first. DOR will be assessed in patients who had an objective response.

    Time frame: up to approximately 3 years

  6. Tumor marker response (AFP, PIVKA-II)

    The decrease of \>20% in serum concentration of each marker from baseline across all time points during study period.

    Time frame: through study completion, up to approximately 3 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2026, 40 months.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's 40 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Mar 2026 → Feb 2026 and completion Mar 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 15, 2023
StartActual
Oct 22, 2022
Primary completionActual
Feb 25, 2026was Mar 2026
CompletionActual
Feb 25, 2026was Mar 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Primary completion
Mar 2026→Feb 25, 2026 (actual)
Nov 9, 2026
Study completion
Mar 2026→Feb 25, 2026 (actual)
Nov 9, 2026
Sponsor
Collaborators added: Hanyang University Guri Hospital; collaborators removed: Hanyang University
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Primary completion Mar 2026→Feb 25, 2026 (now actual)
    Study completion Mar 2026→Feb 25, 2026 (now actual)
    Sponsor Collaborators added: Hanyang University Guri Hospital; collaborators removed: Hanyang University
    + 6 other changes: identifiers, verification date, oversight details, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05992220
Collaborators
Seoul National University Hospital, Hanyang University Guri Hospital, Soon Chun Hyang University
Responsible party
Ju Hyun Shim (Principal Investigator, Asan Medical Center) — Principal investigator
First posted
Aug 15, 2023
Start date
Oct 22, 2022
Primary completion
Feb 25, 2026
Completion
Feb 25, 2026
Last update
Nov 9, 2026

Study contacts

Ju Hyun Shim
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion